The prognostic values of estrogen receptor alpha and beta in patients with gastroesophageal cancer

A meta-analysis

Dongyun Zhang, MDa,*, Jianwei Ku, MDb, Yingjie Yi, MMC, Junhui Zhang, MMd, Rongzhi Liu, MMa, Nianya Tang, MMa

Abstract

Background: Published studies have investigated the prognostic roles of estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) in gastroesophageal cancer patients with the controversial results. The aim of the study was to systematically evaluate the impacts of ERα and ERβ on the overall survival (OS) in patients.

Method: Relevant eligible studies were extracted from PubMed, Embase, Web of Science, CNKI and Wanfang databases (from the start date to November 2018) following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. HR (hazard ratio) with 95% confidence intervals (CIs) were used to assess the prognostic values of ERα and ERβ for OS in patients.

Results: High ERα expression was associated with poor OS (HR = 1.58, 95% CI = 1.29–1.94, P < .001) and ERβ with better OS (HR = 0.56, 95% CI = 0.37–0.83, P = .004) in gastroesophageal cancer. Furthermore, unfavorable OS was found in Chinese gastroesophageal cancer patients with higher ERα expression (HR = 1.57, 95% CI = 1.25–1.96, P < .001) and better OS with higher ERβ expression (HR = 0.51, 95% CI = 0.31–0.83, P < .01) in our subgroup analysis. Meanwhile, worse OS was found in esophageal squamous cell carcinoma (ESCC) patients with high ERα expression (HR = 1.74, 95% CI = 1.33–2.26, P < .001), and favorable OS in ESCC with ERβ overexpression (HR = 0.40, 95% CI = 0.31–0.52, P < .001). Besides, high ERα expression was associated with lower tumor differentiation in ESCC (OR = 1.64; 95% CI = 1.02–2.64, P = .04) and ERβ was linked with better tumor differentiation in gastric adenocarcinoma (GCA) (OR = 0.49; 95% CI = 0.26–0.94, P = .03).

Conclusions: ERα and ERβ might serve as potential prognostic biomarkers for gastroesophageal cancer patients. ERα overexpression predicted poor OS and lower tumor differentiation, and ERβ suggested favorable OS and better tumor differentiation. Further related studies should be performed to test these results.

Abbreviations: 95% CIs = 95% confidence intervals, CNKI = China National Knowledge Infrastructure, ERα = estrogen receptor alpha, ERβ = estrogen receptor beta, ESCC = esophageal squamous cell carcinoma, GCA = gastric adenocarcinoma, HR = hazard ratio, NOS = Newcastle–Ottawa Scale, OR = odds ratios, OS = overall survival.

Keywords: estrogen receptor, gastroesophageal cancer, meta-analysis, overall survival

1. Introduction

Gastroesophageal cancer, consists of stomach and esophagus cancers, is one of the most common and leading reasons of tumor related mortality worldwide.11 Globally, esophageal cancer ranks eighth for cancer incidence and sixth for cancer death, while gastric cancer ranks fourth and second, respectively.21 Clinically, many patients have locally advanced of metastasis at the diagnosis time, and some patients develop recurrence after treatment.31 The late detection and rapid progression may be responsible for the higher mortality and lower survival rate following diagnosis. Therefore, the novel treatments and reliable biomarkers are urgent needed for the predictive and prognosis of gastroesophageal cancer patients.

Estrogen performs biological function, including cell growth and differentiation, by binding to their nuclear hormone receptors subtypes i.e., estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ).41 Several previous studies have reported that estrogen receptor is more than a predictive marker but a prognosis biomarker in cancer with the controversy results.11–111 Tadahiro et al31 and our group61 reported that ERα-positive/ERβ-negative expressions indicate poor overall survival (OS) in patients with
esophageal cancer, especially in esophageal squamous cell carcinoma (ESCC) patients. And it is the same result in gastric adenocarcinoma (GCA) reported by Xu et al.[7] Whereas, Dong et al.[8] and Masashi et al.[10] suggested that downregulation of ERα and upregulation of ERβ may indicate unfavorable prognosis of ESCC. We performed a comprehensive systematic review and meta-analysis to better understand and evaluate the prognostic values of ERα and ERβ in gastroesophageal cancer, which will be further facilitate the identification of novel therapeutic strategies.

2. Methods

The meta-analysis was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Furthermore, the study was conducted by reviewing the published papers, thus, the patients’ informed consent and the ethical approvals were not supplied.

2.1. Publication searching

The eligible studies published in PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases were searched using the following subject heading terms and keywords (gastroesophageal neoplasm OR gastroesophageal cancer OR esophageal neoplasm OR esophageal cancer OR stomach neoplasms OR gastric neoplasm) AND (estrogen receptors OR estrogen nuclear receptor OR estrogen receptor type I OR estrogen receptor type II) AND (prognosis OR survival OR outcome). The specific strategy for the databases was presented in the Supplementary material 1, http://links.lww.com/MD/D363. Additionally, the reference lists of the relevant studies were also manually screened for potentially eligible studies. The displayed language was limited to English and Chinese.

2.2. Inclusion and exclusion criteria

Inclusion criteria for this meta-analysis were: full text available with cross-sectional study, cohort study or case-control study in gastroesophageal cancer; detection of ER expression in primary tissue samples; OS and/or clinicopathological features were investigated; the sufficient relevant data or higher dots per inch of K-M survival curves were available to calculate hazard ratio (HR). Besides, the exclusion standards were: cell or animal studies; case report or comment; no sufficient relevant data or higher dots per inch of K-M survival curves were available to calculate hazard ratio (HR). The eligible studies published in PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases were searched using the following subject heading terms and keywords (gastroesophageal neoplasm OR gastroesophageal cancer OR esophageal neoplasm OR esophageal cancer OR stomach neoplasms OR gastric neoplasm) AND (estrogen receptors OR estrogen nuclear receptor OR estrogen receptor type I OR estrogen receptor type II) AND (prognosis OR survival OR outcome). The specific strategy for the databases was presented in the Supplementary material 1, http://links.lww.com/MD/D363. Additionally, the reference lists of the relevant studies were also manually screened for potentially eligible studies. The displayed language was limited to English and Chinese.

2.3. Data extraction and quality assessment

Two investigators (Jianwei Ku and Yingjie Yi) independently extracted the data from included studies and the disagreement points were resolved by consensus. The following details were extracted: first author name, publication year, patient origin, type of cancer, detection method, number of patients, clinicopathological parameters, effect size, and so on. One study can be evaluated from 3 aspects of selection, comparability, and exposure by the Newcastle–Ottawa Scale (NOS).[12] A maximum of 1 star can be awarded to an article for selection or exposure, and 2 stars for comparability. Thus, 1 study with above to 6 stars was usually considered to be high-quality study.

2.4. Statistical analysis

All statistical analyzes were conducted using the RevMan5.2 and STATA software (version 12.0, STATA Corporation, College Station, TX, USA). 95% confidence intervals (CIs) with Hazard ratio (HR) and/or odds ratios (OR) were combined to evaluate the prognostic and clinicopathologic values. For studies that only offered Kaplan–Meier curves, Engauge Digitizer (version 4.1) was used to extract the survival data and calculate the estimated HR and 95% CIs according to Tierney method.[13] Heterogeneity was assessed using Cochrane Q test and I² measurement.[14] P < .1 or I² > 50% indicate a significant heterogeneity. If heterogeneity existed, a random effect model was applied.[11] And if not, the fixed effect model.[16] Sensitivity analysis was performed to further the stability of the pooled results. Begg[17] and Egger[18] tests were deemed to quantitatively evaluate the extent of publication bias with P value of less than .05.

3. Results

3.1. literature research and characteristics

A total of 319 articles were identified by electronic search and 36 articles were excluded because of duplication. After reading the titles and abstracts, 207 articles were excluded. 76 possible full texts were carefully reviewed. Finally, a total of 7 eligible publications with 11 retrospective cohort studies involving 1874 patients were included for in-depth quantitative analysis.[5–11] The detailed flow chart was presented in Figure 1. These included literatures published from 2010 to 2017, and the sample sizes ranged from 83 to 866. One literature were from Korea,[11] 2 literatures were from Japan[5,10] and 4 literatures were from China.[6–9] The cancer types of the included studies were ESCC and GCA. Of these 7 articles with 11 studies, 1 article with 2 OS studies was not included clinicopathologic parameters.[8] other 6 articles with 9 OS studies based on tissue sample to explore the prognostic and clinicopathologic values.[5–7,9–11] The survival index of OS was conducted in all studies. The expressions of ERα and ERβ were measured by immunohistochemistry. The features of included studies were presented in Table 1.
3.2. Overexpression of ER\textsubscript{a} and ER\textsubscript{b} with prognostic value

All of 6 OS studies concentrated ER\textsubscript{a} investigation in gastroesophageal cancer,\textsuperscript{[5–10]} 4 studies provided OS for ESCC and 2 studies for GCA. A fixed effect model was used to calculate the pooled HR and 95% CI due to the low heterogeneity (\(P = .090, I^2 = 48\%\)). The result showed that higher ER\textsubscript{a} expression was associated with poor OS (HR = 1.58, 95% CI = 1.29–1.96, \(P < .001\)) (Fig. 2A). Additionally, other 5 OS studies reported the prognosis impact of ER\textsubscript{b} in gastroesophageal cancer.\textsuperscript{[5–7,9,11]} The pooled HR for OS was 0.56 (95% CI = 0.37–0.83, \(P = .004\)) with high heterogeneity (\(I^2 = 72\%, P = .007\)) (Fig. 2B).

Subsequently, we conducted subgroup analysis to explore the potential heterogeneity sources. Firstly, subgroup analysis based on geographic area was conducted. Unfavorable OS was found in Chinese gastroesophageal cancer patients with higher ER\textsubscript{a} expression (HR = 1.57, 95% CI = 1.25–1.96, \(P < .001\)) and better OS with higher ER\textsubscript{b} expression (HR = 0.51, 95% CI = 0.31–0.83, \(P = .007\)) (Fig. 3A, B). It did not remained statistically significance for patients derived from no-China (Japan and Korea) area irrespective of patients with ER\textsubscript{a} (HR = 1.73, 95% CI = 0.67–4.44, \(P = .26\)) or ER\textsubscript{b} expression (HR = 0.71; 95% CI = 0.29–1.73, \(P = .45\)) (Fig. 3C, D).

Additionally, subgroup analysis of OS was also performed based on ESCC and GCA. The pooled HR estimate for OS was 1.74 (95% CI = 1.33–2.26, \(P < .001\)) for ESCC patients and 1.51 (95% CI = 0.83–2.76, \(P = .18\)) for GCA patients with higher ER\textsubscript{a} expression (Fig. 4A, C). Subgroup analysis also suggested the better OS with higher ER\textsubscript{b} expression (HR = 0.40, 95% CI = 0.31–0.52, \(P = .001\)) in ESCC, not in GCA patients (HR = 0.69, 95% CI = 0.41–1.17, \(P = .17\)) (Fig. 4B, D).

3.3. Overexpression of ER\textsubscript{a} and ER\textsubscript{b} with clinicopathologic parameters

In present study, 1874 tissue samples were collected to detect the expression levels of ER\textsubscript{a} and ER\textsubscript{b} in gastroesophageal cancer.\textsuperscript{[1–10]} 4 studies provided OS for ESCC and 2 studies for GCA. A fixed effect model was used to calculate the pooled HR and 95% CI due to the low heterogeneity (\(P = .090, I^2 = 48\%\)). The result showed that higher ER\textsubscript{a} expression was associated with poor OS (HR = 1.58, 95% CI = 1.29–1.96, \(P < .001\)) (Fig. 2A). Additionally, other 5 OS studies reported the prognosis impact of ER\textsubscript{b} in gastroesophageal cancer.\textsuperscript{[5–7,9,11]} The pooled HR for OS was 0.56 (95% CI = 0.37–0.83, \(P = .004\)) with high heterogeneity (\(I^2 = 72\%, P = .007\)) (Fig. 2B).

Subsequently, we conducted subgroup analysis to explore the potential heterogeneity sources. Firstly, subgroup analysis based on geographic area was conducted. Unfavorable OS was found in Chinese gastroesophageal cancer patients with higher ER\textsubscript{a} expression (HR = 1.57, 95% CI = 1.25–1.96, \(P < .001\)) and better OS with higher ER\textsubscript{b} expression (HR = 0.51, 95% CI = 0.31–0.83, \(P = .007\)) (Fig. 3A, B). It did not remained statistically significance for patients derived from no-China (Japan and Korea) area irrespective of patients with ER\textsubscript{a} (HR = 1.73, 95% CI = 0.67–4.44, \(P = .26\)) or ER\textsubscript{b} expression (HR = 0.71; 95% CI = 0.29–1.73, \(P = .45\)) (Fig. 3C, D).

Additionally, subgroup analysis of OS was also performed based on ESCC and GCA. The pooled HR estimate for OS was 1.74 (95% CI = 1.33–2.26, \(P < .001\)) for ESCC patients and 1.51 (95% CI = 0.83–2.76, \(P = .18\)) for GCA patients with higher ER\textsubscript{a} expression (Fig. 4A, C). Subgroup analysis also suggested the better OS with higher ER\textsubscript{b} expression (HR = 0.40, 95% CI = 0.31–0.52, \(P = .001\)) in ESCC, not in GCA patients (HR = 0.69, 95% CI = 0.41–1.17, \(P = .17\)) (Fig. 4B, D).

3.3. Overexpression of ER\textsubscript{a} and ER\textsubscript{b} with clinicopathologic parameters

In present study, 1874 tissue samples were collected to detect the expression levels of ER\textsubscript{a} and ER\textsubscript{b} in gastroesophageal cancer. The average expression rates of ER\textsubscript{a} and ER\textsubscript{b} were 70.6%, 67.8% in all studies, respectively. The associations between ER\textsubscript{a} and ER\textsubscript{b} with clinicopathologic parameters including gender, tumor invasion depth, lymph node metastasis, TNM stage, and
tumor differentiation were studied based on ESCC and GCA. Higher ERα expression was linked with tumor low and/or undifferentiation in ESCC (OR = 1.64, 95% CI = 1.02–2.64, P = .04). Two studies with 1034 tissues revealed a statistically correlations between high ER expression and better tumor differentiation in GCA (OR = 0.49, 95% CI = 0.26–0.94, P = .03). No significant association was revealed in other clinicopathologic features (Table 2).

3.4. Publication bias and sensitivity analysis
No obvious asymmetry was presented through the visual assessment of the Begg funnel plots (Fig. 5). Egger test also failed to find the significant bias. Sensitivity analysis was conducted to justify the influence of individual study on the synthetic results of OS. The pooled HR was stable after omitting 1 study each time (Fig. 6).

4. Discussion
The present study included 7 eligible articles with 11 cohort studies and a total of 1874 patients. This was the 1st meta-analysis to estimate the prognostic values of ERα and ERβ in gastroesophageal cancer. Our results revealed that high ERα expression was correlated with worse prognosis whereas ERβ with better OS. ERα overexpression in cancer tissues suggested poor OS and lower tumor differentiation for patients. Furthermore, based on tissue samples from cancer patients, the correlation between higher expression of ERβ and better OS and well tumor differentiation was also statistically significance.

ERα is largely associated with poor prognosis in breast, prostate, ovarian, and endometrial cancer. Studies in ERα knock-out mice found that ERα is required for the onset of mammary tumor development and prostate cancer progression. ERβ activation reduces proliferation and angiogenesis in ER-positive breast cancer cell lines and tumor formation in mice. Our results showed that ERα and ERβ expression were also linked with OS in gastroesophageal cancer. One previous study in our laboratory found that ESCC patients with ERα negative (−)/ERβ positive (+) have a better OS than those with ERα (+)/ERβ(+) and ERα (+)/ERβ(−) expression.

The role of ERβ in tumor suppression is highly dependent on the co-expression of ERα. ERα and ERβ share 96% homology in the DNA-binding region and 59% in the ligand-binding
Table 2

Subgroup analysis: the association of ERα and ERβ expression with clinicopathologic parameters.

| Subgroup type | Variables                  | No. study | OR (95% CI) | Z, P (OR) | Heterogeneity (I², P bias) | Pooling model |
|---------------|----------------------------|-----------|-------------|-----------|---------------------------|---------------|
| **ERα**       |                            |           |             |           |                           |               |
| **ESCC**      | Gender (male/female)       | 2         | 3.77 (0.41–34.68) | 1.17, 0.24 | 67%, .08                  | RE            |
|               | T stage (T3 + T4/T1 + T2)  | 3         | 0.65 (0.22–1.95)  | 0.77, 0.44 | 84%, .002                 | RE            |
|               | N (positive/negative)      | 3         | 0.87 (0.20–3.69)  | 0.19, 0.85 | 90%, <.0001               | RE            |
|               | TNM (II + III + IV)        | 3         | 1.45 (0.75–2.80)  | 1.10, 0.27 | 37%, .20                  | RE            |
|               | differentiation (poor/well) | 3         | 1.64 (1.02–2.64)  | 2.04, 0.04 | 0%, .36                   | FE            |
| **GCA**       | Gender (male/female)       | 2         | 1.16 (0.79–1.71)  | 0.74, 0.46 | 0%, .67                   | FE            |
|               | T (T3 + T4/T1 + T2)        | 1         | 0.93 (0.26–3.03)  | 4.36, 0.0001 | NR                     | NR            |
|               | N (positive/negative)      | 2         | 0.52 (0.11–2.42)  | 0.83, 0.40 | 93%, .0001               | RE            |
|               | TNM (II + III + IV)        | 1         | 0.30 (0.20–0.47)  | 5.41, 0.0001 | NR                     | NR            |
|               | differentiation (poor/well) | 2         | 0.68 (0.10–4.84)  | 0.39, 0.70 | 92%, .0003               | RE            |
| **ERβ**       |                            |           |             |           |                           |               |
| **ESCC**      | Gender (male/female)       | 1         | 0.26 (0.05–1.28)  | 1.65, 0.10 | NR                       | NR            |
|               | T stage (T3 + T4/T1 + T2)  | 2         | 1.02 (0.67–1.54)  | 0.08, 0.94 | 22%, .26                 | RE            |
|               | N (positive/negative)      | 2         | 0.76 (0.53–1.15)  | 1.24, 0.21 | 0%, .93                  | FE            |
|               | TNM (II + III + IV)        | 2         | 1.00 (0.42–2.86)  | 0.18, 0.86 | 0%, .82                  | FE            |
|               | differentiation (poor/well) | 2         | 0.45 (0.11–1.82)  | 1.12, 0.26 | 61%, .11                 | RE            |
| **GCA**       | Gender (male/female)       | 3         | 1.27 (0.93–1.72)  | 1.52, 0.13 | 0%, .76                  | FE            |
|               | T stage (T3 + T4/T1 + T2)  | 2         | 0.54 (0.15–1.96)  | 0.93, 0.35 | 69%, .003                | RE            |
|               | N (positive/negative)      | 3         | 0.91 (0.67–1.22)  | 0.52, 0.64 | 33%, .23                 | FE            |
|               | TNM (II + III + IV)        | 1         | 0.90 (0.54–1.47)  | 0.43, 0.66 | NR                       | NR            |
|               | differentiation (poor/well) | 2         | 0.49 (0.26–0.94)  | 2.16, 0.03 | 0%, .55                  | FE            |

*statistical significance.
CI = confidence interval, FE = fixed effect model, N = lymph node metastasis, OR = odds ratio, RE = random effect model, T = tumor invasion depth.
However, cell-specific expression patterns of alternatively spliced receptor isoforms play a role in mediating the diverse responsiveness to ligand binding.[28,29] ERβ activation is proliferative in ERα(−) cancers,[30,31] and ERβ is tumor suppressive in ERα positive breast cancer.[32,33]

Subgroup analysis also displayed that ERα was largely associated with unfavorable OS and ERβ with better OS in Chinese patients, which was consistent with the results of overall analysis. No significant associations of ERα and ERβ with OS were observed in non-China patients (Japan and Korea). The results suggested that ethnicity might account for the heterogeneity sources. Another possible reasons may be due to the fact that most of patients were mainly from China, and there were only 17.1% (321/1874) non-Chinese patients which results in the selection bias. Further related research should be conducted in other regions.

Although the present study revealed that the overexpression of ERα and ERβ were linked with prognosis and tumor differentiation for gastroesophageal cancer patients, there were some limitations in the meta analysis. First of all, the quality of included studies is with selection bias due to the deletion of some unqualified literatures. Secondly, the screening of language is only English and Chinese, which could not represent the whole population. Finally, the publication bias could not be completely eliminated due to some unpublished studies with negative or null results.

In conclusion, ERα and ERβ in tissues are tumor biomarkers with prognostic and clinicopathologic values for gastroesophageal cancer, and ERα overexpression predicted poor prognosis, lower tumor differentiation and ERβ expression suggested better prognosis and better tumor differentiation. More related research is required to testify these results.

**Author contributions**

Data curation: Dongyun Zhang, Jianwei Ku, Yingjie Yi, Nianya Tang.

Formal analysis: Junhui Zhang, Rongzhi Liu.

Investigation: Junhui Zhang.

Methodology: Jianwei Ku, Yingjie Yi, Nianya Tang.

Project administration: Dongyun Zhang.

Resources: Jianwei Ku, Rongzhi Liu.

Software: Yingjie Yi, Junhui Zhang.

Supervision: Dongyun Zhang.

Writing – original draft: Dongyun Zhang.

Writing – review & editing: Dongyun Zhang, Jianwei Ku, Rongzhi Liu, Nianya Tang.

**References**

[1] Adair T, Hoy D, Detrick Z, et al. Trends in oral, pharyngeal and oesophageal cancer mortality in Australia: the comparative importance of tobacco, alcohol and other risk factors. Aust N Z J Public Health 2011;35:212–9.

[2] Du X, Hidavat K, Shi BM. Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies. Biosci Rep 2017;37:1–9.

[3] Pang X, Wei W, Leng W, et al. Radiotherapy for gastric cancer: a systematic review and meta-analysis. Tumour Biol 2014;35:387–96.
[4] McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptors. Science 2002;296:1642–4.

[5] Tadahiro N, Tsunehiro O, Mitsuhiro T, et al. Significance of immunohistochemical expression of estrogen receptors α and β in squamous cell carcinoma of the esophagus. Clin Cancer Res 2007;13:4046–50.

[6] Zhang DY, Ku JW, Liu R, et al. Characterization of serum estradiol level and tissue estrogen receptor immunostaining with clinical response and reproductive factor changes in Chinese female patients with esophageal squamous cell carcinoma. Biomed Pharmacother 2017;93:879–84.

[7] Xu CY, Guo JL, Jiang ZN, et al. Prognostic role of estrogen receptor α and estrogen receptor β in gastric cancer. Ann Surg Oncol 2010;17:2503–9.

[8] Dong J, Jiang SW, Niu Y, et al. Expressions of estrogen receptor α and β in esophageal squamous cell carcinoma. Oncol Rep 2013;30:2771–6.

[9] Gan L, He J, Zhang X, et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer 2012;12:666–9.

[10] Masashi Z, Yasuhiro M, Yoshiaki O, et al. Estrogen receptor α and β in esophageal squamous cell carcinoma. Cancer Sci 2012;103:1348–55.

[11] Ryu WS, Kim JH, Jang YJ, et al. Expression of estrogen receptors in esophageal squamous cell carcinoma. Oncol Rep 2013;30:2771–6.

[12] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603.

[13] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;7:16–21.

[14] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

[15] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.

[16] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.

[17] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.

[18] Egger M, Davey SG, Schneider M. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629–34.

[19] Pearce ST, Jordan VC. The biological role of estrogen receptors α and β in cancer. Crit Rev Oncol Hematol 2004;50:3–22.

[20] Ali S, Coomber RC. Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 2000;5:271–81.

[21] Bocchinfuso WP, Hively WP, Couse JF, et al. A mouse mammary tumor virus Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 1999;59:1869–76.

[22] Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 1997;2:323–34.

[23] Strom A, Hartman J, Oster JS, et al. Estrogen receptor beta inhibits 17b-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004;101:1366–71.

[24] Hartman J, Lindberg K, Morani A, et al. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006;66:11207–13.

[25] Guillette TC, Jackson TW, Belcher SM. Duality of estrogen receptor beta action in cancer progression. Curr Opin Pharmacol 2018;41:66–73.

[26] Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87:905–31.

[27] Kuiper GGJM. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor. Endocrinology 1998;139:4232–63.

[28] Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011;11:597–608.

[29] Prossnitz ER, Arterburn JB, Smith HO, et al. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2007;69:905–31.

[30] Kupper GGJM. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor. Endocrinology 1998;139:4232–63.

[31] Fox EM, Davis RJ, Shupnik MA. ER beta in breast cancer onlooker, passive player, or active protector? Steroids 2008;73:1039–51.

[32] Haldose LA, Zhao C, Dahlman WK. Estrogen receptor β inhibits angiogenesis and growth of T47D breast cancer xenografts. Annu Rev Physiol 2008;70:165–90.

[33] Omo N, Shupnik MA. Estrogen receptor β in breast cancer. Endocr Relat Cancer 2013;20:127–39.

[34] Fox EM, Davis RJ, Shupnik MA. ER beta in breast cancer onlooker, passive player, or active protector? Steroids 2008;73:1039–51.

[35] Omoto Y, Iwase H. Clinical significance of estrogen receptor? In breast and prostate cancer from biological aspects. Cancer Sci 2015;106:337–43.

[36] Haldose LA, Zhao C, Dahlman WK. Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 2014;382:665–72.